Xspray Pharma: Update after Dasynoc CRL - Redeye
Bildkälla: Stockfoto

Xspray Pharma: Update after Dasynoc CRL - Redeye

Redeye updates its view on Xspray following last week’s CRL delaying the approval of Dasynoc. Based on the currently available information, we expect a new PDUFA date in either Q2 or Q3 next year and have adjusted our fair value range accordingly.

Redeye updates its view on Xspray following last week’s CRL delaying the approval of Dasynoc. Based on the currently available information, we expect a new PDUFA date in either Q2 or Q3 next year and have adjusted our fair value range accordingly.
Börsvärldens nyhetsbrev